SUNNYVALE, Calif. (BUSINESS WIRE) May 25, 2006 Intraop Medical Corporation (OTCBB: IOPM) has received an order from Saint Augustinius Hospital, Antwerp, Belgium, for the Company's proprietary Mobetron system. The Mobetron is an FDA-approved, easily transportable electron-beam instrument designed for Intraoperative Radiation Therapy (IORT), or the direct application of radiation to a tumor while a patient is undergoing cancer surgery. St. Augustinius will be the first hospital in Belgium to offer IORT, but the eighth treatment center in Europe to use the Mobetron.

"We are pleased to have this prominent Belgian institution join the growing list of Mobetron users in Europe. Based on the interest we are seeing for IORT and the Mobetron, especially for early-stage breast cancer, we believe Europe will continue to be a strong and expanding market for us, converting the demand into revenues for the Company," said Dr. Donald A. Goer, President and Chief Executive Officer of Intraop. "The Mobetron, when integrated into a hospital's cancer program, produces excellent clinical results and can save weeks of conventional external beam radiation, as well as patients' lives. This makes the Mobetron a very important, cost-effective treatment option."

Saint Augustinius intends to use its Mobetron to treat a variety of tumors, including early-stage breast cancer. The Mobetron to be delivered to St. Augustinius was previously rented to Catharina Zeikenhuis in Eindhoven, the Netherlands for interim use while the hospital was constructing a shielded operating room. Catharina treated more than 160 patients with the Mobetron during this time.

Dr. Goer continued: "Our successful remarketing of this Mobetron demonstrates the high resale value of our equipment. The fact that the Mobetron has already been used in the Netherlands saved St. Augustinius four to five weeks of expensive commissioning, allowing its doctors to begin treating patients sooner."

About Saint Augustinius Hospital

St. Augustinius is a 600-bed hospital located in Antwerp, Belgium that specializes in utilizing innovative high-technology medical equipment in the service of its patients. The hospital uses a comprehensive, multidisciplinary approach to treating cancer, integrating surgery, radiation therapy and chemotherapy treatments as appropriate. St. Augustinius treats about 2,000 cancer patients per year. With the addition of the Mobetron, IORT will form an important component of their comprehensive multidisciplinary approach.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.